February 23, 2018
Sanofi in closure of $11.6 billion hemophilia specialist buy
Sanofi’s waiting period to complete the purchase of Bioverativ has came to an end, and will thus expand its hemophilia and other…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Bioverativ
January 22, 2018
Sanofi goes shopping, buys Bioverativ, for $11.6 billion, adds hemophilia and other rare blood disorders specialist to the basket
Sanofi will buy Bioverativ Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders, for $11,6…
May 24, 2017
Bioverativ buys San Francisco-based True North Therapeutics
Bioverativ has acquired South San Francisco-based True North Therapeutics, a privately-held, clinical-stage rare disease biotechnology company, for an upfront payment of $400 million plus assumed cash.
March 2, 2017
Sobi nets EMA’s approval for higher capacity drug substance for Elocta
Swedish Orphan Biovitrum (Sobi) has received approval from the European Medicines Agency (EMA) for the grouped type II 15 K Variation for Elocta (efmoroctocog alfa), recombinant extended half-life factor VIII Fc fusion protein product for the treatment of haemophilia A.